A revolutionary technology developed within the Trabolsi Research Group at NYU Abu Dhabi (NYUAD) can dramatically improve the well-being of diabetic patients: an insulin oral delivery system that replaces traditional subcutaneous injections without the side effects caused by frequent injections Can.
Using prepared layers of nanosheets with insulin between the layers to protect it, the researchers developed gastro-resistant imine-linked-covalent organic framework nanoparticles (NCOFs), which demonstrate insulin protection in the stomach, as well In diabetes test subjects whose sugar levels have fully returned to normalization within two hours of swallowing the nanoparticles.
The research was published today in Chemical Science under the leadership of Research Scientist Farah Bennettu of NYUAD and Program Head of Chemistry Ali Trabolasi.
Compared to the two FDA-approved techniques for oral delivery of insulin, the system developed at NYUAD is biocompatible, highly stable in the stomach, specific, and capable of delivering the correct amount of insulin based on the blood sugar level of the diabetic subject. is. This treatment represents a step forward in treating the disease, which is the seventh leading cause of death worldwide.
“Our work overcomes the barriers to insulin oral delivery using insulin-loaded nCOF nanoparticles, which exhibit increased insulin protection as well as glucose-responsive release in the stomach.” He said, “This technique reacts quickly to increased blood sugar, but will stop immediately to prevent excess insulin and dramatically improve the well-being of diabetic patients in the United Arab Emirates and around the world, ” They said.
Using prepared layers of nanosheets with insulin between the layers to protect it, the researchers developed gastro-resistant imine-linked-covalent organic framework nanoparticles (NCOFs), which provide for insulin protection in the stomach as well as diabetes test subjects. Also, those whose sugar levels have fully returned to normal within two hours of swallowing the nanoparticles.
The findings were published in Chemical Science (“In Vivo Oral Insulin Delivery Through Covalent Organic Structures”), led by NYUAD’s Research Scientist Farah Bennettu and Program Head of Chemistry Ali Trabolsey.
Compared to the two FDA-approved techniques for oral delivery of insulin, the system developed at NYUAD is biocompatible, highly stable in the stomach, specific, and capable of delivering the correct amount of insulin based on the blood sugar level of the diabetic subject. is. This treatment represents a step forward in the treatment of the disease which is the seventh leading cause of death worldwide.
“Our work overcomes the barriers to insulin oral delivery using insulin-loaded nCOF nanoparticles, which exhibit increased insulin protection as well as glucose-responsive release in the stomach.” He said, “This technique reacts quickly to increased blood sugar, but will stop immediately to prevent excess insulin and dramatically improve the well-being of diabetic patients in the United Arab Emirates and around the world, ” They said.
The treatment was developed in collaboration with an international team of researchers from Algeria, Spain, Saudi Arabia and the United Kingdom. The project was completed with the help of core platform technology of NYUAD. A US patent application is pending for this innovative technology.